Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Polymyositis

Diseases of the Musculoskeletal System and Connective Tissue

Polymyositis is a type of chronic muscle inflammation related to dermatomyositis and inclusion body myositis; its name comes from the Greek for many, muscle and inflammation. The inflammation is found mainly in the endomysial layer of skeletal muscle, in contrast to dermatomyositis, which is characterized primarily by inflammation of the perimysial layer.

Facts
Classification
Body System
Muscular System 1
ICD-10 Chapter
XIII: Diseases of the Musculoskeletal System and Connective Tissue 2
Communicable or Non-communicable
Non-Communicable 3
Transmission Route
Non-Transmissible 3
Connections

Treated By

Immunosuppressive therapy is the standard treatment for polymyositis.

Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Polymyositis, lead section
Quote, https://en.wikipedia.org/wiki/Polymyositis, lead section
Polymyositis (PM) is a type of chronic inflammation of the muscles related to dermatomyositis and inclusion body myositis. Its name is derived from poly- 'many', myos- 'muscle' and -itis 'inflammation'. The inflammation of polymyositis is mainly found in th
View the Source
2. Wikipedia: ICD-10
WikipediaList of chapters, Chapter XIII
Quote, List of chapters, Chapter XIII
Diseases of the musculoskeletal system and connective tissue
View the Source
3. Wikipedia: Non-communicable disease
Wikipedia
  • Lead section, transmission-route statement (inferred from disease-category)
    NCDs include Parkinson's disease, autoimmune diseases, strokes, heart diseases, cancers, diabetes, chronic kidney disease, osteoarthritis, osteoporosis, Alzheimer's disease, cataracts, and others.
  • Named examples section
    NCDs include Parkinson's disease, autoimmune diseases, strokes, heart diseases, cancers, diabetes, chronic kidney disease, osteoarthritis, osteoporosis, Alzheimer's disease, cataracts, and others.
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.